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Evidence for biphasic uncoating during HIV-1
infection from a novel imaging assay
Hongzhan Xu1, Tamera Franks1, Gregory Gibson2, Kelly Huber1, Nadia Rahm3, Caterina Strambio De Castillia3,4,
Jeremy Luban3,4, Christopher Aiken5, Simon Watkins2, Nicolas Sluis-Cremer1 and Zandrea Ambrose1*
Abstract
Background: Uncoating of the HIV-1 core plays a critical role during early post-fusion stages of infection but is
poorly understood. Microscopy-based assays are unable to easily distinguish between intact and partially uncoated
viral cores.
Results: In this study, we used 5-ethynyl uridine (EU) to label viral-associated RNA during HIV production. At early
time points after infection with EU-labeled virions, the viral-associated RNA was stained with an EU-specific dye and
was detected by confocal microscopy together with viral proteins. We observed that detection of the
viral-associated RNA was specific for EU-labeled virions, was detected only after viral fusion with target cells, and
occurred after an initial opening of the core. In vitro staining of cores showed that the opening of the core allowed
the small molecule dye, but not RNase A or antibodies, inside. Also, staining of the viral-associated RNA, which is
co-localized with nucleocapsid, decays over time after viral infection. The decay rate of RNA staining is dependent
on capsid (CA) stability, which was altered by CA mutations or a small molecule inducer of HIV-1 uncoating. While
the staining of EU-labeled RNA was not affected by inhibition of reverse transcription, the kinetics of core opening
of different CA mutants correlated with initiation of reverse transcription. Analysis of the E45A CA mutant suggests
that initial core opening is independent of complete capsid disassembly.
Conclusions: Taken together, our results establish a novel RNA accessibility-based assay that detects an early event
in HIV-1 uncoating and can be used to further define this process.
Background
The replication cycle of HIV-1 is complex; while many
of the critical steps have been described in great detail,
some, including uncoating of the viral core, remain
poorly understood. After fusion with the host cell, HIV-
1 releases the core into the cytoplasm. The core contains
the conical viral capsid, composed of a polymer of capsid
protein (CA) subunits, encasing the viral RNA (vRNA)
genome. The viral RNA undergoes reverse transcrip-
tion, forming viral DNA (vDNA) in the cytoplasm. The
vDNA together with the nucleocapsid (NC), reverse tran-
scriptase (RT), Vpr, and integrase (IN) form the pre-
integration complex (PIC). The PIC is transported to the
nucleus by way of microtubules and actin filaments in
the cytoplasm [1,2], and subsequently enters the nucleus
by mechanisms which have only recently begun to be
examined in detail [3]. Inside the nucleus, the HIV-1
DNA is integrated into host cell chromatin, after which
the provirus is transcribed for viral protein expression
for particle assembly and release from the cell.
The stability of the HIV-1 capsid has been linked to
reverse transcription and nuclear entry. CA mutations
that alter the intrinsic stability of the capsid have
profound effects on reverse transcription [4] and entry
of viral DNA into the nucleus [5-8]. In addition, the rhe-
sus macaque tripartite interaction motif 5α protein
(rhTRIM5α) is a restriction factor that inhibits HIV-1
and other retroviruses by targeting the viral capsid and
inhibiting reverse transcription [9], likely by perturbing
the capsid structure. Proteasome inhibitors relieve the
block to reverse transcription by rhTRIM5α, suggesting
that this restriction targets the reverse transcription
complex (RTC) for proteasomal degradation [10]. In
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addition, the RTC requires cellular factors for comple-
tion of reverse transcription that are independent of CA
mutations that alter core stability [11,12]. Despite the
importance of the structure and stability of the viral cap-
sid in HIV-1 infection, the process of uncoating, which
we define as dissociation of the capsid from the core, re-
mains poorly understood, mainly owing to difficulties in
the detection of HIV-1 cores soon after entry into target
cells. A recent study described the development of as-
says measuring association of HIV-1 Vpr and CA in
HeLa cells, and the timing of escape from TRIMCyp-
mediated restriction in owl monkey cells. Using these
novel approaches, the authors reported that uncoating
could be delayed for a virus with a hyperstable capsid or
by preventing reverse transcription, further reinforcing
the functional connection between HIV-1 uncoating and
reverse transcription [13].
Despite recent advances in studies of the structure and
stability of the HIV-1 capsid, uncoating remains poorly
understood and is not currently possible to study by
live-cell imaging techniques due to lack of available
methods to label CA molecules without perturbing the
function of the viral capsid. Fluorescence microscopic
methods to track the core and viral protein or DNA
components of the RTC/PIC have been employed previ-
ously [1,2,14-16], but are limited in terms of sensitivity.
To circumvent these problems, we applied an alternative
method of labeling HIV-1 RNA such that it could be
stained with a fluorescent small molecule dye after cap-
sid dissociation in vitro or during cell infection. The dye
is specific for virus particle-associated RNA and can only
access the viral nucleic acid after an initial uncoating
step that appears to involve opening of the capsid. We
observed that the kinetics of RNA staining were altered
by the presence of rhTRIM5α or TRIMCyp, by CA sub-
stitutions altering capsid stability, and by addition of a
small molecule inducer of HIV-1 uncoating. Surpris-
ingly, the previously identified E45A CA mutant, which
exhibits hyperstable cores in vitro, exhibited efficient
staining of viral-associated RNA through cores in vitro
and accelerated staining kinetics in vivo, suggestive of a
permeable capsid.
Results
HIV-1 RNA staining in virions requires CA core opening
To label and track HIV-1 RNA intracellularly, we incor-
porated a modified nucleoside, 5-ethynyl uridine (EU),
into vRNA during virus production. Detection of alkyne-
modified nucleosides in vRNA was performed by select-
ive ligation of an azide-containing fluorescent dye to
the modified nucleoside, in a so-called a “click” reaction
[17], and subsequent fluorescent confocal microscopy of
infected target cells. Because HIV-1 particles can incorp-
orate cellular mRNA from the producer cell [18-20], the
modified virus-associated RNA could, in principle, be
both cellular and viral in origin.
HIV-1 particles were made by transfecting 293T cells
with a proviral construct and a plasmid encoding VSV-G
in the presence of EU for different lengths of time to
optimize vRNA labeling and normal viral protein pro-
duction. EU was added to the transfection medium for
the first 16 h of transfection, the last 24 h of transfec-
tion, or the entire 48 h of transfection. To test whether
EU-labeled viruses were infectious, viruses produced in
the presence of EU incorporation for different lengths of
time were assayed for infectivity in HIV-1 indicator cells
as well as for total CA production. For HIV-1 produced
in the presence of 1 mM EU for 16 h, the specific infect-
ivity, or infectious units (IU) per ng of CA antigen, was
comparable to that of control virus made in the absence
of EU (Table 1). Viruses produced in the presence of EU
during the entire 48 h of transfection or for the last 24 h
of transfection exhibited 2- and 3-fold lower infectivity
relative to unlabeled HIV-1. Furthermore, decreased
yields of virus were produced during extended culture
time in EU, which was likely due to increased cellular
toxicity of 293T cells incubated for longer periods of
time with 1 mM EU (Additional file 1: Figure S1). Subse-
quent experiments were performed using 0.1 - 0.4 mM
EU during 48 h of virus production to minimize cell tox-
icity. Viral DNA from cells infected with EU-labeled
virus was sequenced and revealed no difference in muta-
tions compared to unlabeled virus (data not shown),
suggesting that EU incorporation does not affect reverse
transcription.
To determine if the EU-binding dye could penetrate
intact cores, we treated EU-labeled HIV-1 particles with
cell extraction buffer or buffer containing lysates from
293T cells or 293T cells expressing rhTRIM5α. The re-
striction factor rhTRIM5α has been reported to disrupt
HIV-1 cores and assembled CA tubes in vitro [21-23].
To visualize stained and unstained particles, infectious
virus containing a genome with MS2 protein binding
sites was produced in cells expressing the MS2-GFP fu-
sion protein and incubated with EU. Co-localization of
vRNA staining and MS2-GFP was greater than 75%,
Table 1 Specific infectivity (infectious units per ng p24)
of EU-labeled viruses
Virus p24 (ng/ml) ± SD Specific infectivity
No DNA <0.008 0
No EU 191 ± 3 1510
EU for 1st 16 h 28 ± 4 2230
EU for 2nd 24 h 165 ± 4 500
EU for 48 h 20 ± 1 820
D443N 107 ± 10 8
SD, standard deviation of duplicate measurements.
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whereas particles without MS2-binding sites showed a
background of 8% co-localization of EU staining and
GFP (Additional file 1: Table S1 and Figure S2). Particles
were fixed to slides and stained for EU (Figure 1A). Few
particles stained for vRNA when treated with buffer
alone, which permeabilizes the viral membrane. How-
ever, normal cell lysate increased staining of the vRNA,
suggesting that cellular factors may promote dye entry
into the core. vRNA staining was also observed in parti-
cles subjected to cell lysate containing rhTRIM5α, which
leads to disruption of the capsid. Without an intact CA
core to protect it, vRNA should be sensitive to RNase A
treatment, leading to its degradation. With RNase A
added to the particles exposed to rhTRIM5α, signifi-
cantly fewer vRNA puncta were detected by staining
in vitro compared to virions without RNase A treatment
(Figure 1B). However, virions treated with normal 293T
cell lysate and RNase A showed no decrease in vRNA
staining, suggesting that the small dye (approximately
268 Da), but not the larger enzyme (12.7 kDa), could
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Figure 1 EU staining of HIV-1 RNA in vitro. (A) EU-labeled virus encoding MS2-binding sites and produced in the presence of MS2-GFP (green)
was treated with cell extraction buffer, 293T cell lysate, or 293T cell lysate containing rhTRIM5α for 15 minutes, fixed onto slides, and then stained
for EU (red). Particles were visualized by fluorescent confocal microscopy and shown for each individual color and with both colors (merge). (B)
MS2-GFP+ and EU+ virions were counted per field after treatment with buffer, 293T cell extract, or 293T cell extract expressing rhTRIM5α in the
presence of 10 μg/ml RNase A. Data represent the ratio of double positive particles of the total counted MS2-GFP+ particles ± SEM of at least 4
fields. Results are representative of 2 independent experiments. A student’s t test was performed on medium vs. RNase A treatment of virions
incubated with either 293T or 293T-rhTRIM5α lysate. NS denotes a non-significant p value (>0.05).
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access the RNA. Particles made without MS2-GFP also
showed significant loss of vRNA staining in the presence
of 10 and 100 μg/ml RNase A (Additional file 1: Figure S3).
Labeled HIV-1 RNA is detected in infected cells
To visualize EU-labeled virus-associated RNA in cells,
TZM-bl cells were infected with virus-containing trans-
fection supernatants and fixed, permeabilized, and stained.
Viruses produced in the presence or absence of EU were
incubated with TZM-bl cells for 2 h before washing and
staining (Figure 2A). The cells infected with EU-labeled
virus had detectable punctate staining in the cytoplasm,
whereas the cells infected with unlabeled virus did not. Un-
infected cells did not show any staining (data not shown).
Pseudotyping HIV-1 with the vesicular stomatis virus gly-
coprotein G (VSV-G) was used to ensure high infectivity
levels of the virus and to compare different cell lines that
may not have significant levels of CD4 or co-receptors.
VSV-G allows viral entry via endocytosis rather than cell
membrane fusion by HIV-1 envelope [24,25]. Fusion rates
assessed by imaging studies have shown VSV-G to be ac-
celerated compared to HIV-1 CXCR4-tropic envelope
(15 minutes vs. 48 minutes) [13]. While it is unknown
whether the route of entry will affect downstream events,
the previous study did not show a difference in the timing
of intracellular uncoating based on entry pathway.
To determine whether or not virus-associated RNA
staining detected HIV-1 prior to fusion and entry into
cells, virus was produced in the presence of EU and the
membrane-associated S15-Cherry protein [26]. Thus,
vRNA was labeled with EU (green) and viral membranes
were labeled with S15-mCherry (red). A loss of mCherry
B
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Figure 2 EU-labeled HIV-1 can be visualized intracellularly. (A) RNA staining (red) of TZM-bl cells after infection for 2 h with equal
multiplicities of infection of EU-labeled virus (labeled during the first 16 h of transfection) or unlabeled virus. (B) Viral membrane-associated
S15-mCherry (red) is incorporated into MS2-GFP+ (green) virions prior to infection (top), but is not co-localized with EU-labeled WT HIV-1 RNA
staining (green) after incubation with cells (bottom). Viruses labeled with EU and S15-mCherry were used to infect TZM-bl cells for 1 h and
stained for EU. DAPI was used to stain nuclei (blue). MS2-GFP or EU and S15-mCherry are shown individually and overlayed together (merge).
The panels are representative of multiple fields.
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signal indicates that virus particles have fused with the
cell or endosomal membrane. S15-mCherry was effi-
ciently incorporated into virions as shown in particles
containing a packagable viral genome with binding sites
for the bacteriophage MS2 protein and produced in cells
expressing MS2-GFP fusion protein (Figure 2B). When
EU- and mCherry-labeled particles were added to cells,
some mCherry particles on or between cells were ob-
served even after extensive washing. However, vRNA
staining was not co-localized with mCherry in any fields,
suggesting that the EU staining was specific for intracel-
lular virus-associated RNA. This was expected, as the
dye does not permeate through lipid bilayers, including
viral membranes.
Labeled HIV-1 RNA maintains co-localization with NC but
not Vpr or CA after infection
Analysis of GFP-Vpr-labeled HIV-1 virions detected
GFP-Vpr in association with CA in approximately 80%
of particles [2]. Following HIV-1 entry into the cyto-
plasm, CA and GFP-Vpr co-localization decreases over
time, which is thought to be due to uncoating [13].
Therefore, we asked whether EU-labeled vRNA of in-
coming particles would be co-localized with CA and
GFP-Vpr. Cells were inoculated with EU-labeled virus
that also contained co-packaged GFP-Vpr, and were sub-
sequently stained for EU and with antibodies against CA
(Figure 3A). Many particles exhibited RNA staining, CA
staining, or GFP-Vpr alone. At 15 minutes post-
infection, the percentage of EU staining that was co-
localized with CA or with GFP-Vpr was 76% or 27%,
respectively (Figure 4A). However, at 1 hour post-infection
the percentage of EU staining with CA decreased signifi-
cantly to 9% and decreased slightly with GFP-Vpr to
18% of the time. This is consistent with the hypothesis
that CA molecules are rapidly removed from the core
during uncoating. The frequency of detectable CA and
GFP-Vpr puncta declined over time (Figure 4B), suggesting
that cores had uncoated and these RTC components had
diffused in the cytosol. Accordingly, we observed diffuse
signals for EU-labeled RNA at later time points after infec-
tion as compared to mostly bright, punctate staining at
earlier time points (Additional file 1: Figure S4).
HIV-1 nucleocapsid (NC) has been shown to bind
vRNA and act as a chaperone during vDNA synthesis
[27]. Therefore, vRNA should remain associated with
NC in the core and throughout reverse transcription
after uncoating. To determine if EU-labeled vRNA was
co-localized with NC, staining for NC by monoclonal
antibodies together with EU staining was performed in
HIV-1 infected cells (Figure 3B). While NC and GFP-
Vpr could be detected alone, vRNA staining was co-
localized with NC much more than with GFP-Vpr or
CA at 1 h post-infection. NC and vRNA co-localization
occurred 71% after 15 minutes and 66% after 1 h post-
infection (Figure 4A), suggesting that EU detection was
specific for virus-associated RNA. By contrast to GFP-
Vpr and CA, NC detection did not diminish over time
in the infected cells, suggesting that the particles were
not being totally degraded (Figure 4B).
Intracellular HIV-1 RNA staining increases within
30 minutes post-infection and is affected by rhTRIM5α
and TRIMCyp
Next we performed a time course in which TZM-bl cells
were infected with WT HIV-1 in a synchronized manner
for 15–30 minutes and fixed at different time points
thereafter. Virus-associated RNA was stained and quan-
tified (Figure 5A). The number of counted EU-stained
spots per cell, as measured by DAPI staining of nuclei,
was determined for 4 fields for each time point with ap-
proximately 10 – 40 cells counted per field. We ob-
served an average of 0.6 – 10 EU-stained spots per cell
after 15 – 30 minutes of incubation with the various vi-
ruses and conditions tested (Additional file 1: Figure S5).
The number of vRNA puncta decreased between 45 and
150 minutes post-infection, which was coincident with
diffusion of the signal over time (Additional file 1: Figure
S4). The kinetics of vRNA detection after HIV-1 infec-
tion of TZM-bl cells showed a reproducible initial in-
crease in EU-containing vRNA staining from 30 to
45 minutes, followed by a decrease thereafter. Because
new vRNA molecules likely cannot be synthesized dur-
ing early post-entry time points, it is possible that the
AlexaFluor azide stain requires opening of the CA core
in the cytoplasm in order to gain access to the viral gen-
ome, consistent with the results of staining viruses
in vitro (Figure 1). A similar effect is seen for antibody
staining of NC (Figure 4B), which is presumably bound
to vRNA inside the core. An increase in GFP-Vpr or CA
staining was not observed.
rhTRIM5α has been shown to bind to HIV-1 capsids
and to restrict HIV-1 infection prior to reverse tran-
scription in vivo [9,28]. This restriction factor has also
been reported to disrupt HIV-1 cores and assembled CA
tubes in vitro [21-23]. We therefore examined the effects
of rhTRIM5α on the kinetics of staining of virus-
associated RNA. When cells expressing rhTRIM5α were
infected with EU-labeled viruses, we observed a small
initial increase in the number of detectable vRNA be-
tween 15 – 25 min post-infection that decreased rapidly,
and the low level of staining remained fairly stable dur-
ing the time course of up to 270 minutes (Figure 5A).
This difference compared to normal TZM-bl cells may
be due to more rapid and complete disruption of the in-
coming CA cores by the restriction factor, allowing the
stain to access vRNA earlier.
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Figure 3 EU-labeled WT HIV-1 RNA is co-localized with NC in cells. TZM-bl cells were infected for 1 h with EU-labeled virus containing
GFP-Vpr (green) and stained for (A) RNA (cyan) and CA (red) or (B) RNA (cyan) and NC (red). DAPI was used to stain nuclei (blue). Cells were then
visualized by fluorescent confocal microscopy. Arrows indicate co-localization of vRNA with CA or NC staining when both colors are merged
(white). Results are representative of multiple independent experiments.
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Similarly, owl monkey kidney (OMK) cells express
TRIMCyp, a fusion protein of TRIM5α and cyclophilin
A, that restricts HIV-1 infection and can be reversed by
inhibiting TRIMCyp binding to CA with the drug cyclo-
sporine A (CsA) [29,30]. OMK cells were infected with
EU-labeled WT HIV-1 and stained for RNA between 15 –
90 minutes post-infection (Figure 5B). Like cells express-
ing rhTRIM5α, these cells expressing TRIMCyp did not
show an early increase in RNA staining. This staining pat-
tern was reversed in cells treated with CsA, suggesting
that when the TRIMCyp restriction was relieved, there
was a delay in vRNA staining owing to restoration of nor-
mal uncoating.
The RNase H activity of RT cleaves the vRNA in
RNA-DNA hybrids formed during reverse transcription,
and we wondered whether RNase H-dependent degrad-
ation is responsible for the observed decrease in vRNA
staining over time. To test this, we made EU-labeled
HIV-1 containing the D443N amino acid substitution in
RT. This mutant leads to a loss of RNase H activity,
leading to incomplete reverse transcription [31]. As a re-
sult, this mutant had almost a 190-fold decrease in spe-
cific infectivity as compared to WT HIV-1 (Table 1),
despite having similar levels of viral particles. The vRNA
staining assay revealed that D443N HIV-1 had a similar
decay curve as WT HIV-1 in TZM-bl cells (Figure 5C),
indicating that vRNA degradation was not due to viral
RNase H activity. These results also indicated that pre-
mature termination of reverse transcription does not
alter the kinetics of vRNA staining.
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Figure 4 Quantification of viral proteins co-localized with WT HIV-1 RNA over time in cells. (A) After HIV-1 infection of TZM-bl cells, RNA
staining was counted alone and when co-localized with CA, GFP-Vpr, or NC at 15 min and 60 min post-infection. The percentage of co-localized
events for at least four fields was calculated. (B) CA, GFP-Vpr, and NC puncta were quantified at multiple time points post-infection. The first time
point was normalized to 1. Data represent the mean ± SEM of at least 4 fields. Asterisks denote statistically significant p values (p < 0.05) between
time points for each viral protein or at each time point, comparing NC with CA or with GFP-Vpr. NS denotes a non-significant p value (>0.05).
Results are representative of 2 independent experiments.
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Figure 5 The kinetics of HIV-1 RNA staining is affected by rhTRIM5α/TRIMCyp but independent of reverse transcription. (A) TZM-bl cells
or TZM-bl cells expressing rhTRIM5α were infected with WT HIV-1 and stained for EU at multiple time points. The inset shows staining from a
second experiment at earlier time points. (B) OMK cells were infected with WT HIV-1 in the presence or absence of CsA and stained for EU at
multiple time points. (C) TZM-bl cells were infected with WT HIV-1 or the D443N RT mutant and stained for EU at multiple time points. 0.6 - 13.5
vRNA puncta were detected per cell. Data represent the mean ± SEM of at least 4 fields and the first time point was normalized to 1. Asterisks
denote statistically significant p values (p < 0.05) at each time point between the two lines. The graphs are representative of 2
independent experiments.
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Perturbation of HIV-1 CA capsid stability by mutations or
a drug alters vRNA staining kinetics
To determine whether vRNA staining kinetics reflect
core opening after HIV-1 infection, we stained vRNA at
multiple time points after infection of TZM-bl cells with
HIV-1 CA mutants exhibiting alterations in capsid sta-
bility (Figure 6A). The CA K203A mutant was previously
shown to have highly unstable cores and low infectivity
[4]. K203A vRNA staining began to decay after 25 mi-
nutes post-infection instead of after 55 minutes post-
infection observed for WT HIV-1. Moreover, K203A
HIV-1 did not show the usual transient increase in
vRNA staining typically observed for wild type HIV-1,
suggesting that CA core opening for this mutant oc-
curred within 15 – 25 minutes post-infection. This ob-
servation was similar to the data for WT HIV-1 in
rhTRIM5α-expressing cells (Figure 5A). A quintuple mu-
tant, Q67H/K70R/H87P/T107N/L111I, designated 5Mut
and recently described as having a hyperstable capsid [32],
showed stable vRNA for up to 75 minutes post-infection
(Figure 6A). Together, these data suggest that the kinetics
of vRNA staining and decay are related to HIV-1 un-
coating during infection.
Interestingly, E45A HIV-1, which had previously been de-
scribed as having a hyperstable capsid and lower infectivity
as compared to WT HIV-1 [4,33], exhibited a rapid vRNA
decay profile that was similar to that of K203A. However,
unlike the K203A mutant, E45A HIV-1 had an increase in
vRNA staining between 15 – 25 minutes post-infection,
followed by a significant decline at 35 minutes post-
infection (Figure 6A). These data indicate that the capsid of
E45A HIV-1 dissociated early after infection. The E45A
phenotype was partially reversed with the addition of the
mutation of R132T, resulting in a double mutant for which
EU staining resembled WT HIV-1. The E45A/R132T mu-
tant is more infectious than the E45A mutant, indicating
that the functional defect induced by E45A is partially res-
cued by R132T [34].
To further examine whether capsid stability affects the
kinetics of vRNA decay, we tested the effect of PF74, a
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Figure 6 Viral RNA staining is altered by mutations that affect capsid stability. TZM-bl cells were infected with (A) EU-labeled WT, E45A,
K203A, 5Mut, and E45A/R132T HIV-1; or (B) EU-labeled WT and 5Mut HIV-1 in the presence and absence of 10 μM PF74. 0.6 - 4.4 vRNA puncta
were detected per cell. Data represent the mean ± SEM of at least 4 fields and the first time point was normalized to 1. Asterisks denote
statistically significant p values (p < 0.05) between WT and each mutant or with or without PF74 treatment at each time point. The graphs are
representative of 2 independent experiments.
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small molecule inhibitor that destabilizes the HIV-1 cap-
sid [32,35], in our assay (Figure 6B). We infected TZM-
bl cells with WT HIV-1 in the presence of PF74 and
observed accelerated vRNA decay relative to infection
in the absence of the compound. Whereas WT vRNA
staining began to decay after 45 minutes post-infection
in untreated cells, PF74 led to lower vRNA staining at
the first time point, showing no transient increase in
vRNA staining that is observed with most viruses in cells
without the CA inhibitor, similar to the unstable K203A
mutant. In contrast, the PF74-resistant 5Mut virus [32]
was efficiently stained with the EU dye for extended
times, and its staining was unaffected by infection in the
presence of PF74.
CA E45A HIV-1 cores are more permeable than WT
HIV-1 cores
Because of the unexpected rapid RNA staining of E45A
HIV-1, we hypothesized that the integrity of E45A capsid
is compromised by the mutation, allowing molecules,
such as antibodies and the fluorescent dye, to enter the
core more rapidly. To determine whether E45A cores
allow entry of different molecules into the core more
easily than WT CA cores, equal amounts of EU-labeled
WT HIV-1 and E45A HIV-1 particles in buffer (2.5 ng
CA) were fixed onto slides and stained for EU by the small
dye and for NC by monoclonal antibodies (Figure 7A).
Similar to the previous results shown in Figure 2A, we
observed little RNA staining of WT vRNA. In addition, we
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Figure 7 E45A HIV-1 cores allow vRNA and NC staining more readily than WT HIV-1 cores. (A) Equal amounts of p24 of EU-labeled WT
HIV-1 and E45A HIV-1 were treated with cell extraction buffer for 15 minutes, fixed onto slides, and then stained for EU (green) and NC (red).
Particles were visualized by fluorescent confocal microscopy. (B) RNA staining of WT HIV-1 and E45A HIV-1 was counted alone and when
co-localized with NC. The percentage of co-localized events for at least four fields was calculated. Data represent the mean ± SEM of at least
4 fields. (C) Equal amounts of p24 of EU-labeled WT HIV-1 and E45A HIV-1 also containing MS2-GFP (green) were treated with cell extraction
buffer for 15 minutes, fixed, and stained for EU (red). Particles were visualized by fluorescent confocal microscopy and shown for each individual
color and with both colors (merge).
Xu et al. Retrovirology 2013, 10:70 Page 10 of 16
http://www.retrovirology.com/content/10/1/70
saw almost no staining of NC for the WT virions. How-
ever, we observed both viral-associated RNA and NC
staining in E45A virions, suggesting that both the small
molecule dye and the anti-NC antibodies could penetrate
the cores. The co-localization of NC and viral-associated
RNA in E45A cores was approximately 65%, whereas it
was only approximately 10% for WT cores (Figure 7B). In
addition, EU-labeled E45A HIV-1 particles containing
MS2-GFP were stained and showed higher levels of stain-
ing compared to WT MS2-GFP particles (Figure 7C).
Because HIV-1 requires a cell factor(s) for completion
of reverse transcription [12], it is possible that premature
opening of the core might lead to earlier initiation of re-
verse transcription. If this is the case, a core that re-
mains closed longer should exhibit slower production of
viral DNA. To test this, we quantified early (RU5) re-
verse transcription products in cells infected with equal
quantities of WT HIV-1 and mutant virions (Figure 8).
Indeed, we observed a more rapid accumulation of early
reverse transcripts for E45A HIV-1 as compared to WT
HIV-1, K203A HIV-1, or 5Mut HIV-1. The level of
E45A reverse transcripts was 2-fold higher than the WT
vDNA level at 15 minutes post-infection that continued
to increase above WT HIV-1 reverse transcripts during
the time course. By contrast, the level of reverse tran-
scripts for the K203A and 5Mut viruses did not increase
over the 155-minute time course. The results for early
reverse transcripts for the K203A mutant were consist-
ent with previous reports looking at significantly later
time points [4,5], which may be due to a completely un-
stable core that leads to poor infectivity for this virus
[4,36]. In contrast, E45A HIV-1 has detectable infectivity
(20-30-fold lower than WT HIV-1) [6,36], perhaps
allowing more efficient initiation of reverse transcription
to occur if the core partially uncoated or opened earlier.
Late reverse transcripts did not increase significantly for
the viruses during this short time course (data not
shown).
Discussion
One aspect of HIV-1 biology that is just beginning to be
understood is the process of uncoating of the core fol-
lowing viral entry into the cell. Uncoating appears intim-
ately linked to reverse transcription, as mutations that
destabilize the capsid generally impair reverse transcrip-
tion in target cells [4], as do restrictive TRIM5 proteins
[9,37]. Completion of reverse transcription may also re-
quire capsid dissociation, allowing the RTC to come into
contact with putative positive-acting intracellular factors
that facilitate viral DNA synthesis [11,12]. Reverse tran-
scription may also promote later stages of uncoating;
perhaps the size and rigidity of double-stranded viral
DNA formed during reverse transcription may help to
destabilize the CA lattice and may not physically fit in-
side of the core [13]. However, a structural and molecu-
lar understanding of uncoating and its role in reverse
transcription remain unresolved.
In the present study, we describe the detection of
intracellular HIV-associated RNA during infection. The
modified nucleoside, EU, is incorporated into viral and
cellular RNA in the producer cell. Fluorescent azide
molecules can efficiently and selectively engage RNA-
incorporated EU in a “click” reaction after entry into the
CA core. We did not observe significant background
staining of uninfected cells or cells infected with un-
labeled HIV-1. Neither the virus-associated RNA signal
nor the decay of this signal required reverse transcrip-
tion or viral RNase H activity, which may be the result
of a loss of signal of the labeled RNA after dissociation
of the CA core and diffusion in the cytosol. The EU sig-
nal persisted for up to 4 hours, but the staining became
more diffuse over time. vRNA was largely associated
with NC but less so with CA or GFP-Vpr, especially as
the infection progressed. This was not surprising, since
HIV-1 NC favors binding to single-stranded RNA and
assists RT with various steps during reverse transcription
[27,38]. In contrast, CA has been shown previously to
dissociate within 40–60 minutes post-infection, and over
50% of the GFP-Vpr signal is lost between 1 and 2 hours
post-infection [13], which is consistent with our results.
Our assay showed a steady, reproducible loss of HIV-1
RNA detection with time, consistent with uncoating and
the proposed instability of HIV-1 RNA in the cytosol
[39]. The kinetics were affected by manipulating capsid
stability by mutations or a small molecule CA inhibitor.
The K203A CA mutant, which has been described as
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Figure 8 Initiation of reverse transcription was more rapid in
E45A HIV-1 compared to WT, K203A, and 5Mut HIV-1. Early viral
reverse transcripts (RU5) were measured by qPCR from TZM-bl cells
infected with equal p24 levels of WT, E45A, K203A, and 5Mut HIV-1.
Data represent the mean ± SEM of duplicates and are normalized for
μg of total isolated DNA. Asterisks denote statistically significant p
values (p < 0.05) between WT and each mutant at each time point.
The graph is representative of 2 independent experiments.
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having a more fragile core than WT [4,13], showed more
rapid loss of vRNA staining. Similarly, cells infected with
WT HIV-1 that were treated with PF74, a capsid-
destabilizing compound [32], showed much more rapid
vRNA decay than in untreated cells. Conversely, the
5Mut CA mutant that has a very stable core [32] had
more persistent detection of EU-labeled RNA that did
not decline appreciably for up to 75 minutes post-
infection and did not show vDNA accumulation during
that time period. 5Mut particles are resistant to PF74
antiviral action and capsid destabilization, which ex-
plains the similar vRNA staining that we observed for
this virus in the presence and absence of the drug. Inter-
estingly, the infectivity of 5Mut particles is similar to
WT [40], suggesting that a hyperstable capsid is not an
impediment to HIV-1 infection, at least in some target
cells.
While it seems likely that the decay of HIV-1 CA
staining in HeLa cells over time also reflects uncoating,
as shown recently [13], its rapid decline and loss of sig-
nal (t1/2 of approximately 1–2 hours post-infection) sug-
gests that the immunochemical assay is detecting a
major uncoating event in which most CA molecules dis-
associate from the RTC within 1 hour post-infection.
Due to the difficulty in obtaining reproducible staining
quantitation of sufficient number of particles, the CA
staining assay lacks the requisite sensitivity to identify
subtle changes in capsid structure and the extent of
uncoating. By contrast, the EU staining assay relies on
RNA accessibility to a small molecule dye, and the rapid
increase in staining observed for wild type HIV-1 sug-
gests that RNA cannot be accessed by the dye until an
initial event occurs in the presence of cellular factors.
This was evident when looking at infection of cells be-
tween 15 – 45 minutes post-infection with WT HIV-1
and different CA mutants, and in biochemical studies
with permeabilized virions. We also observed an in-
crease in detection of NC, which should be contained
within the core, between 30 and 75 minutes after infec-
tion. This initial opening did not lead to an immediate
loss of CA staining, suggesting that EU staining reflects
a more subtle uncoating step occurring prior to bulk dis-
sociation of CA from the core. We also detected cellular
accumulation of vDNA only after 75 minutes of virus in-
oculation, suggesting that reverse transcription proceeds
after access to the cytosol.
The putative early uncoating event reflected by RNA
staining also appeared to be inhibited by rhTRIM5α and
TRIMCyp restriction factors. rhTRIM5α engages the
capsid prior to reverse transcription and binds to assem-
bled capsids, leading to their disruption [9,21,23,28].
Similarly, TRIMCyp leads to capsid disassembly that is
prevented by CsA treatment [29,30]. Our RNA accessi-
bility assay results are consistent with the interpretation
that these restriction factors disrupt the HIV-1 capsid
and the effects of TRIMCyp restriction on vRNA stain-
ing could be reversed by CsA treatment, which prevents
restriction.
Previously, Hulme et al. showed that complete uncoating,
as measured by GFP-Vpr and CA co-localization, or by
escape from TRIMCyp by timed CsA withdrawal [13],
is delayed by treatment by an RT inhibitor, suggesting
that reverse transcription promotes uncoating. Our results
showed that inhibition of reverse transcription did not
alter the kinetics of RNA accessibility, suggesting that the
early uncoating event required for RNA exposure is not
dependent on reverse transcription and consistent with a
recent study showing the fate of viral core components
during premature uncoating [39]. It is possible that human
cell factors induce an initial uncoating event to allow re-
verse transcription to continue such that complete dissoci-
ation of the core can occur. It is also possible that the early
uncoating event results in permeabilization of the core to
small molecules, such as dNTPs, required for reverse
transcription.
It was surprising that the E45A mutant, which was de-
scribed as having a more stable capsid than WT HIV-1
[4], consistently exhibited RNA accessibility kinetics that
resembled those of mutants with unstable capsids. In
contrast to the K203A mutant, cytoplasmic E45A cores
initially exhibited a small transient increase in RNA
staining between 15 and 25 minutes post-infection, simi-
lar to WT cores. This was followed by a rapid decrease
in vRNA staining as observed for the unstable K203A
mutant. Furthermore, reverse transcription was initiated
more rapidly for E45A HIV-1 as compared to WT HIV-
1 or the other mutants tested. Importantly, the second-
site suppressor mutation, R132T, partially restored the
E45A RNA staining kinetics to wild type, correlating the
effect of E45A mutation on RNA accessibility with its
impairment of infectivity. Our previous results using
correlative live-cell microscopy and cryo-electron tom-
ography of infected cells suggested that E45A CA cores
disassociate more slowly intracellularly than WT cores
[33]. While the comparable behavior of the K203A and
E45A mutants appears contradictory, it supports the
hypothesis that a subtle HIV-1 CA uncoating event pre-
cedes and is independent of a more extensive dissoci-
ation of CA from the core. We suggest that for the
E45A mutant virus, the first uncoating step occurs more
rapidly than for WT HIV-1 but that the second
uncoating step is delayed relative to WT HIV-1. The
first step would allow an opening for some cellular fac-
tors to access the interior of the core, leading to more
rapid synthesis of early reverse transcripts, consistent
with the results shown here. However, the majority of
the E45A CA remains intact, delaying completion of re-
verse transcription as compared to WT HIV-1. It is
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possible that a multi-step uncoating process is necessary
for both HIV-1 to complete reverse transcription with
cellular factors and allowing the RTC to be somewhat
contained to prevent disassociation of key components
from the complex. Consistently biphasic uncoating of
purified HIV-1 cores has been observed biochemically
[4]. Alternatively, the lattice of E45A CA cores may be
more leaky, allowing small molecules to gain access in-
side. Further high-resolution studies comparing WT and
E45A CA cores are needed to determine if they differ in
lattice structure or flexibility.
Conclusions
In conclusion, we have developed a fluorescence-based
RNA accessibility assay that detects an initial opening of
the HIV-1 capsid. This initial uncoating step may be
triggered by host cell factors and can be influenced by
alteration of the stability of the core by CA mutations or
a small molecule inhibitor. The RNA accessibility assay,
in combination with complementary approaches to de-
tect capsid dissociation, will be useful for studying the
role of cellular factors in the early postentry stages of
HIV-1 infection.
Methods
Cell lines and antiviral compounds
293T cells were used for transfections and for cell lysates
described in assays below. TZM-bl cells are HeLa cells
expressing CD4, CXCR4, and CCR5 that carry the lacZ
and firefly luciferase genes downstream from the HIV-1
LTR [41]. OMK cells are owl monkey kidney cells that
have been shown to express endogenous TRIMCyp
[29,30]. TZM-rhTRIM5α and 293T-rhTRIM5α cells ex-
press rhTRIM5α from the pLPCX-TRIM5a-HA vector,
obtained through the NIH AIDS Research and Reference
Reagent Program from Drs. Joseph Sodroski and Matt
Stremlau. GHOST cells are human osteosarcoma cells
expressing CD4, CXCR4, and CCR5 that carry the GFP
gene downstream from the HIV-2 LTR [42]. All cells
were grown in DMEM and supplemented with 10% fetal
bovine serum and 1% penicillin, streptomycin, and L-
glutamine. PF-3450074 (PF74) [35] was synthesized by
the Vanderbilt Institute of Chemical Biology Synthesis
Core, Vanderbilt University, Nashville, TN. PF74 was
dissolved as a 10 mM stock in DMSO and added to tar-
get cell cultures at a final concentration of 10 μM.
Virus stocks and EU-incorporation
HIV-1 particles were made by transfection of 293T cells
with the following plasmids: pNLdVdE-luc, a plasmid
containing the HIV-1NL4-3 provirus with an early stop
codon in vpr, a deletion in env, and the firefly luciferase
gene in place of nef [6]; GFP-Vpr plasmid, a kind gift
from Dr. Tom Hope [2]; and pL-VSV-G, a plasmid
encoding the envelope glycoprotein from vesicular sto-
matitis virus (VSV) [43]. Particles were also produced
with the S15-mCherry plasmid, a kind gift from Dr.
Tom Hope [26]. The pNLdVdE-luc plasmid had the fol-
lowing CA amino acid substitutions introduced by via
cloning from other HIV-1NL4-3 vectors or PCR mutagen-
esis: E45A, E45A/R132T, K203A, or 5Mut. Similarly,
PCR mutagenesis was used to create pNLdVdE-luc
containing the RT mutation D443N. Transfections were
performed using calcium phosphate or Lipofectamine
2000 in medium containing 0.1 – 1 mM EU (Invitrogen,
Carlsbad, CA) for 48 h. Cell supernatants were collected,
ultracentrifuged through a 20% sucrose cushion to re-
move free EU, resuspended in fresh medium, and frozen
at −80°C in aliquots.
Viruses from transfection supernatants were titered in
GHOST cells in duplicate. Medium was replaced after
2 h and cells were analyzed after 48 h on an LSRII flow
cytometer for GFP expression in <40% of the cells. CA
levels were measured by serial dilutions of supernatants
by p24 ELISA (Zeptometrix, Buffalo, NY) in duplicate.
Additional experiments showing EU co-localization
with virus containing bacteriophage MS2 coat protein
binding sites were performed, using a plasmid encoding
a viral vector sequence containing twelve MS2-binding
sites. The vector was cotransfected with either WT or
E45A pcHelpΔVif [44], a kind gift from Dr. Klaus
Strebel, pL-VSV-G, and pcDNA-MS2GFP, a vector ex-
pressing MS2-GFP, in the presence of 0.4 mM EU. The
transfection medium was replaced with 0.1 mM EU an
additional 32 h. The EU-labeled virions were harvested
by filtering through 0.45 μm syringe filters and purified
through a sucrose cushion. The pelleted virions were
resuspended in 200 μl of fresh DMEM medium with
50% FBS and subjected to imaging analysis. Viruses were
quantified by p24 ELISA.
Viral RNA labeling and viral protein staining in cells
TZM-bl or TZM-rhTRIM5α cells were plated in 8-well
chamber slides and virus was added at 4°C at equal
multiplicities of infection or p24 levels for 30 minutes to
synchronize infections. OMK cells were plated in cham-
ber slides in the presence or absence of 10 μM CsA
(Bedford Laboratories, Bedford, OH). Cells were trans-
ferred to 37°C thereafter for 15 or 30 minutes. Cells
were washed twice with fresh medium and incubated at
37°C for up to 360 minutes. Cells were fixed in 2% para-
formaldehyde (PFA) for 15 minutes, washed with PBS
twice, and permeabilized with 0.05% Triton X in PBS for
15 minutes. The cells were stained with the Click-iT
RNA Imaging Kit with Alexa Fluor 488 or Alexa Fluor
594 (Invitrogen) as per the manufacturer’s instructions.
Staining with anti-CA monoclonal antibody (AG3.0),
obtained through the NIH AIDS Research and Reference
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Reagent Program from Dr. Jonathan Allan [45], and
anti-NC monoclonal antibodies, a kind gift from Dr.
Robert Gorelick, was performed, followed by staining
with anti-mouse IgG-Cy5. Imaging was performed using
an Olympus Fluoview 1000–1 confocal microscope.
RNA and viral protein puncta were enumerated by
Imaris software.
Viral RNA labeling in viral particles
EU-labeled HIV particles were treated with cell extrac-
tion buffer (100 mM sodium chloride, 10 mM Tris
pH 7.5, 1 mM EDTA, 0.5% Triton X-100, 10% glycerol,
1 μg/ml pepstatin, 1 μg/ml aprotinin, 1 μg/ml leupeptin
and 1 mM sodium peroxyvanadate) alone or cell lysates
of 293T cells or 293T-rhTRIM5α cells (2 x107 cells/ml of
cell extraction buffer) for 30 minutes in the presence or
absence of RNase A at room temperature. HIV-1 parti-
cles were fixed with 2% paraformaldehyde in 8-well
chambered #1.0 borosilicate coverglass (Lab-Tek, Scotts
Valley, CA) coated with Cell-Tak (BD Biosciences, San
Jose, CA). The wells were treated with PBS containing
0.05% Triton-X-100 (Fisher Scientific, Pittsburgh, PA)
for 15 minutes and washed with PBS once. vRNA was
stained by the Click-iT RNA Imaging Kit per the manu-
facturer’s instructions and washed 5 times in PBS before
mounting. Imaging was performed using an Olympus
Fluoview 1000–1 Confocal Microscope and staining was
enumerated using Imaris.
qPCR for viral DNA
Viruses were treated with DNase I (60 units/ml) for
30 minutes at 37°C. To control for any contaminating
plasmid carry-over, the plasmid pEGFP-C1 (Clontech,
Mountain View, CA), which does not encode any retro-
viral sequences, was added to the virus prior to infection
(6 × 1010 copies). TZM-bl cells were incubated with
equal amounts of virus particles (5 ng CA per well) for
30 minutes at 4°C. Controls for each virus infected in
the presence of 150 nM of efavirenz was included. After
incubation, virus was removed and fresh medium was
added. Cells were switched to 37°C for further incuba-
tion of 15 min. The plates were washed and incubated
for different lengths of time. Cells were lysed with cell
extraction buffer, mixed with phenol, and stored on ice.
Cellular DNA was purified by phenol-chloroform extrac-
tion and ethanol precipitation. vDNA quantification by
real time PCR could be affected by variations from mul-
tiple steps, including adding virus, removing virus, wash-
ing after infection, cell lysing, DNA purification and
PCR sample loading. To minimize the variation in vDNA
quantification, we used two primer sets in each PCR reac-
tion to detect both reverse transcripts and internal pEGFP-
C1 plasmid. The HIV-1 primers and probes used were
previously described, using FAM/TAMRA [6]. The eGFP
primers used were 5’-tacgtccaggagcgcaccat-3’ (forward) and
5’-cagctcgatgcggttcacca-3’ (reverse) and the probe was 5’-
HEX-acgacggcaactacaagacc-IBFQ-3’. We used a single plas-
mid, pHIV-eGFP [46] (a kind gift from P. Bieniasz) with
both HIV and GFP control sequences as the standard. After
qPCR, reverse transcript levels were normalized by internal
control and any background in the presence of efavirenz
was subtracted, typically 2-4% of the levels measured in the
absence of drug.
Statistics
Paired two-sided student’s t tests were performed to
compare puncta counts for different viral RNA or pro-
teins, viruses, or treatment conditions at individual time
points using Prism (GraphPad Software, La Jolla, CA),
with the exception of comparisons of reverse transcript
results which used an unpaired student’s t test of the
duplicates.
Additional file
Additional file 1: Table S1. EU detection in MS2-GFP + virions. Figure S1.
Toxicity of EU in 293 T cells. (A) Cells were incubated in the presence of cell
culture medium containing 0.5 mM or 1 mM EU for 0, 1, or 3 h. (B) Cells were
incubated in cell culture medium containing 0, 0.25, 0.5, or 1 mM EU
overnight (approximately 16 h). Cell viability was determined by the XTT cell
viability assay (Roche). Error bars represent standard deviations between
duplicate wells. Figure S2. MS2-GFP binding is specific for virus with
genomes containing MS2-binding sites. EU staining (red) of HIV-1 particles
without (left) or with (right) MS2-binding sites produced in cells expressing
MS2-GFP (green). Figure S3. Virus treated with cell lysate containing rhTRIM5α
is sensitive to RNA degradation. EU+ puncta per field were counted for
labeled virus particles treated with 293T cell extract or 293T cell extract
expressing rhTRIM5α in the presence of 0, 1, 10, or 100 μg/ml RNase A. Results
are representative of 2 independent experiments. Data represent the mean ±
SEM of 4 fields. Significant p values (p < 0.05) are listed above each set of bars
as determined by student’s t test. NS denotes p values that are not significant
(p > 0.05). Figure S4. EU staining diffuses over time. EU staining of WT HIV-1
in TZM-bl cells at (A) 15 minutes or (B) 90 minutes post infection. Arrows
denote EU staining. Figure S5. Example of RNA puncta and cell counts per
field prior to normalization. (A) EU + puncta and (B) cells were counted in 4
fields for OMK cells treated with medium or CsA and infected with WT HIV-1.
Data represent the mean ± SEM of 4 fields. Asterisks denote statistically
significant p values (p < 0.05) between CsA or medium at each time point by
student’s t test.
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